Torthaí cuardaigh - Jane Meisel

  • 1 - 13 toradh as 13 á dtaispeáint
Beachtaigh na torthaí
  1. 1
    Overwhelming Watery Diarrhea Associated with a Cryptosporidium in an Immunosuppressed Patient

    Overwhelming Watery Diarrhea Associated with a Cryptosporidium in an Immunosuppressed Patient de réir Jane Meisel, David Perera, C. Meligro, C.E. Rubin

    Foilsithe / Cruthaithe 1976
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  2. 2
    Rectal biopsy in the diagnosis of Crohn's disease: Value of multiple biopsies and serial sectioning

    Rectal biopsy in the diagnosis of Crohn's disease: Value of multiple biopsies and serial sectioning de réir Christina M. Surawicz, Jane Meisel, Thomas J. Ylvisaker, David Saunders, C.E. Rubin

    Foilsithe / Cruthaithe 1981
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  3. 3
    The role of systemic chemotherapy in the management of granulosa cell tumors

    The role of systemic chemotherapy in the management of granulosa cell tumors de réir Jane Meisel, David M. Hyman, Anjali R. Jotwani, Qin Zhou, Nadeem R. Abu‐Rustum, Alexia Iasonos, Malcolm C. Pike, Carol Aghajanian

    Foilsithe / Cruthaithe 2014
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  4. 4
    Stromal PD-L1 Expression Is Associated With Better Disease-Free Survival in Triple-Negative Breast Cancer

    Stromal PD-L1 Expression Is Associated With Better Disease-Free Survival in Triple-Negative Breast Cancer de réir Xiaoxian Li, Ceyda Sönmez Wetherilt, Uma Krishnamurti, Jing Yang, Yamin Ma, Toncred M. Styblo, Jane Meisel, Limin Peng, Momin T. Siddiqui, Cynthia Cohen, Ritu Aneja

    Foilsithe / Cruthaithe 2016
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  5. 5
    Development of a risk stratification system to guide treatment for female germ cell tumors

    Development of a risk stratification system to guide treatment for female germ cell tumors de réir Jane Meisel, Kaitlin M. Woo, Nora Sudarsan, Jana Eng, Sujata Patil, Erin Jacobsen, Rajmohan Murali, Ginger J. Gardner, George J. Bosl, Carol Aghajanian, Darren R. Feldman

    Foilsithe / Cruthaithe 2015
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  6. 6
    TROPION-Breast04: a randomized phase III study of neoadjuvant datopotamab deruxtecan (Dato-DXd) plus durvalumab followed by adjuvant durvalumab versus standard of care in patients with treatment-naïve early-stage triple negative or HR-low/HER2− breast cancer

    TROPION-Breast04: a randomized phase III study of neoadjuvant datopotamab deruxtecan (Dato-DXd) plus durvalumab followed by adjuvant durvalumab versus standard of care in patients... de réir Heather L. McArthur, Sara M. Tolaney, Rebecca Dent, Peter Schmid, Jamil Asselah, Qiang Liu, Jane Meisel, Naoki Niikura, Winnie Yeo, Gustavo Werutsky, Giampaolo Bianchini, Jay C. Andersen, Robert Kozarski, Nana Rokutanda, Barbara Pistilli, Sibylle Loibl

    Foilsithe / Cruthaithe 2025
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  7. 7
    159TiP TROPION-Breast04: Phase (ph) III study of neoadjuvant (neoadj) datopotamab deruxtecan (Dato-DXd) + durvalumab (D) followed by adjuvant (adj) D vs standard of care (SoC) in treatment-naïve, triple-negative (TN) and HR-low/HER2- breast cancer (BC)

    159TiP TROPION-Breast04: Phase (ph) III study of neoadjuvant (neoadj) datopotamab deruxtecan (Dato-DXd) + durvalumab (D) followed by adjuvant (adj) D vs standard of care (SoC) in t... de réir Sibylle Loibl, S.M. Tolaney, P. Schmid, Barbara Pistilli, Rebecca Dent, Jamil Asselah, Q. Liu, Jane Meisel, Naoki Niikura, Y.H. Park, G. Werutsky, Giampaolo Bianchini, J.C. Andersen, R. Kozarski, N. Rokutanda, Heather L. McArthur

    Foilsithe / Cruthaithe 2024
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  8. 8
    A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study)

    A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive brea... de réir Tejal Patel, Joe Ensor, Sarah L. Creamer, Toniva Boone, Angel Rodriguez, Poly A. Niravath, Jorge Darcourt, Jane Meisel, Xiaoxian Li, Jing Zhao, John G. Kuhn, Roberto R. Rosato, Wei Qian, Anna Belcheva, Mary R. Schwartz, Virginia Kaklamani, Jenny C. Chang

    Foilsithe / Cruthaithe 2019
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  9. 9
    Drug-drug interactions between palbociclib and proton pump inhibitors in early breast cancer: an exploratory analysis of PALLAS (ABCSG-42/AFT-05/BIG-14-13/PrE0109)

    Drug-drug interactions between palbociclib and proton pump inhibitors in early breast cancer: an exploratory analysis of PALLAS (ABCSG-42/AFT-05/BIG-14-13/PrE0109) de réir Elisa Agostinetto, Georg Pfeiler, Dominik Hlauschek, Erica L. Mayer, Matteo Lambertini, Evandro de Azambuja, M. Bellet-Ezquerra, Jane Meisel, Gábor Rubovszky, Nicholas Zdenkowski, Yelena Novik, Manuel Ruíz‐Borrego, Karen A. Gelmon, Eleftherios P. Mamounas, Hiroji Iwata, Dongrui R. Lu, Lidija Soelkner, Christian Fesl, Michael Gnant, Angela DeMichele

    Foilsithe / Cruthaithe 2025
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  10. 10
    Gene expression associated with endocrine therapy resistance in estrogen receptor-positive breast cancer

    Gene expression associated with endocrine therapy resistance in estrogen receptor-positive breast cancer de réir Veronica Jones, Hongwei Yin, Yuan Yuan, Yongzhe Wang, Sierra Min Li, Dana Aljaber, Angelica Sanchez, Christine Quinones, Daniel Schmolze, Yuan Yuan, Joanne Mortimer, Lisa D. Yee, Laura Kruper, Tijana Jovanović‐Talisman, Jerneja Tomšič, Nancy Sanchez, Tanya Chavez, Ruth O’Regan, Qamar J. Khan, Melissa B. Davis, Kevin Kalinsky, Jane Meisel, Rick A. Kittles, Lorna Rodrı́guez-Rodrı́guez, Victoria L. Seewaldt

    Foilsithe / Cruthaithe 2025
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  11. 11
    Diverse <i>BRCA1</i> and <i>BRCA2</i> Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer

    Diverse <i>BRCA1</i> and <i>BRCA2</i> Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer de réir Britta Weigelt, Iñaki Comino‐Méndez, Ino de Bruijn, Lei Tian, Jane Meisel, Isaac García-Murillas, Charlotte Fribbens, Ros Cutts, Luciano G. Martelotto, Charlotte K.Y. Ng, Raymond S. Lim, Pier Selenica, Salvatore Piscuoglio, Carol Aghajanian, Larry Norton, Rajmohan Murali, David M. Hyman, Laetitia Borsu, Maria E. Arcila, Jason Konner, Jorge S. Reis‐Filho, Roger A. Greenberg, Mark E. Robson, Nicholas C. Turner

    Foilsithe / Cruthaithe 2017
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  12. 12
    Clinical Cancer Advances 2021: ASCO's Report on Progress Against Cancer

    Clinical Cancer Advances 2021: ASCO's Report on Progress Against Cancer de réir Sonali M. Smith, KERRI WACHTER, Howard A. Burris, Richard L. Schilsky, Daniel J. George, Douglas E. Peterson, Melissa L. Johnson, Merry Jennifer Markham, Kathryn F. Mileham, Muhammad Shaalan Beg, Johanna C. Bendell, Robert Dreicer, Vicki L. Keedy, Randall J. Kimple, Miriam A. Knoll, Noelle K. LoConte, Helen Mackay, Jane Meisel, Timothy J. Moynihan, Daniel A. Mulrooney, Therese M. Mulvey, Olatoyosi Odenike, Nathan A. Pennell, Katherine E. Reeder‐Hayes, Cardinale B. Smith, Ryan J. Sullivan, Robert G. Uzzo

    Foilsithe / Cruthaithe 2021
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  13. 13
    Quality-of-life and symptom severity in the PALLAS randomized trial of palbociclib with adjuvant endocrine therapy in early breast cancer (AFT-05, ABCSG-42, BIG-14-03, PrE0109)

    Quality-of-life and symptom severity in the PALLAS randomized trial of palbociclib with adjuvant endocrine therapy in early breast cancer (AFT-05, ABCSG-42, BIG-14-03, PrE0109) de réir Michelle J. Naughton, D M Zahrieh, Michael Gnant, Nicholas Zdenkowski, Julie Lemieux, Jun J. Mao, Vesna Bjelic‐Radisic, Eileen H. Shinn, Marija Balić, C. Thomssen, Jane Meisel, García Erika Ruiz, Sibylle Loibl, Claudine Isaacs, David Cameron, Fernando Henao, Matthew P. Goetz, C.F. Singer, Gustavo Werutsky, H.S. Rugo, Marcus Vetter, Ling‐Ming Tseng, Kathy D. Miller, Florian Fitzal, Miguel Gil‐Gil, H. Park, B. Linderholm, Emilio Bajetta, Zoneddy Dayao, Aleix Prat, Karl Ehrhardt, Otto Metzger, Amal Arahmani, Ernest H. Law, Ann H. Partridge, Lisa A. Carey, Alex Zoroufy, Amylou C. Dueck, Patrick O’Brien, Dominik Hlauschek, Angela DeMichele, Erica L. Mayer

    Foilsithe / Cruthaithe 2025
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:

Uirlisí cuardaigh: